Cogent Biosciences (COGT) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Krystal Biotech (KRYS) over the past year, gaining 93.1% versus a gain of 74.9%. Over five years, KRYS leads with a +571.8% price change compared with +225.5% for COGT. Krystal Biotech is the larger company by market cap ($9.81 billion vs $5.26 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | KRYS |
|---|---|---|
| Share price | $30.34 | $331.42 |
| Market cap | $5.26B | $9.81B |
| 1-day change | +0.85% | +1.26% |
| YTD return | -15.32% | +32.76% |
| 1-year return | +93.07% | +74.86% |
| 5-year return | +225.54% | +571.80% |
| P/E ratio (TTM) | — | 41.53 |
| Forward P/E | — | 35.76 |
| EPS (TTM) | $-2.16 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $389.13M |
| Revenue growth (YoY) | — | +33.94% |
| Net income (latest FY) | $-328.94M | $204.83M |
| Operating margin | — | 41.45% |
| Net margin | — | 52.64% |
| 52-week high | $43.73 | $382.54 |
| 52-week low | $13.78 | $179.19 |
| Distance from 52-week high | -30.63% | -13.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.01% | +18.31% |
| Average volume | 1.90M | 381.18K |
| Shares outstanding | 173.52M | 29.60M |
| Employees | 258 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed KRYS by 18.2 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
COGT vs KRYS FAQ
Which is bigger, Cogent Biosciences or Krystal Biotech?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.81B compared with $5.26B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or KRYS?
COGT returned +93.07% over the past 12 months, compared with +74.86% for KRYS (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Krystal Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cogent Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Krystal Biotech.